Technology in Cancer Research & Treatment最新文献

{"title":"Pain-Related PANoptosis Gene Signature Predicts Prognosis and Guides Therapy in Oral Squamous Cell Carcinoma.","authors":"Ying Yao, Qi Liu, Silu Chen, Yan Wang, Xiang Gao","doi":"10.1177/15330338261468835","DOIUrl":"10.1177/15330338261468835","url":null,"abstract":"<p><p>IntroductionThis study aimed to develop a prognostic model based on pain-related PANoptosis genes to enhance therapeutic decision-making for oral squamous cell carcinoma (OSCC) patients.MethodsRNA sequencing data from 323 OSCC patients and 43 controls in the TCGA cohort were analyzed to identify differentially expressed genes (DEGs). Correlation analysis revealed pain-related PANoptosis genes, and a prognostic model was developed using Cox and LASSO regression and validated in the GSE42743 cohort. Immune microenvironment differences were assessed, and drug sensitivity was predicted. qRT-PCR was employed to validate gene expression alterations in OSCC tissues.ResultsAmong 2,253 DEGs, 38 overlapped with PANoptosis-related genes, leading to the identification of 37 pain-related PANoptosis genes that characterized two OSCC subtypes. A Pain-Related PANoptosis-gene model (including CA9, DEFB1, DES, IGLL5, LCE3D, LYNX1, SPINK7) achieved AUCs of 0.626 and 0.690 in the TCGA and validation cohorts, respectively. Significant immune microenvironment differences were noted, with high-risk patients showing immune characteristics associated with a more immunosuppressive environment. GSEA identified activated pathways like autophagy and chemokine signaling in high-risk patients.ConclusionsThe pain-related PANoptosis-gene model effectively stratifies OSCC patients by risk. Sepantronium bromide may represent a potential therapeutic candidate for high-risk patients; however, further experimental validation is required.</p>","PeriodicalId":22203,"journal":{"name":"Technology in Cancer Research & Treatment","volume":"25 ","pages":"15330338261468835"},"PeriodicalIF":2.7,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13385609/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148521011","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Dosimetric Performance Analysis of Pediatric Based Halcyon™ Volumetric Arc Therapy-Based Lung-Sparing Total Body Irradiation.","authors":"Allison Haertter, Keshav Goel, Jacob Niculcea, Taoran Li, Christine E Hill-Kayser, John Plastaras, Michael J LaRiviere, Michele M Kim","doi":"10.1177/15330338261443068","DOIUrl":"10.1177/15330338261443068","url":null,"abstract":"<p><p>IntroductionHalcyon™ O-ring linear accelerators (linacs) provide a robust and efficient radiotherapy option for clinics. Interest in volumetric arc therapy (VMAT) based total body irradiation (TBI) has grown, with most current VMAT TBI protocols employing C-arm linacs; however, the feasibility of Halcyon-based VMAT TBI has been recently hypothesized. This study investigates the planning feasibility and dosimetric quality of VMAT-based, lung-sparing TBI delivered by Halcyon linac to pediatric patients.Methods10 pediatric patients (94 - 134 cm in height) previously treated to 12 Gy TBI through traditional 3D planning techniques were retrospectively replanned on a Halcyon linac. 2-3 VMAT plans containing 4-6 isocenters each with 2-2.5 arcs were created to treat the head, abdomen, and legs, with 1-2 static-gantry treatment matching areas being used between VMAT planning regions.ResultsLung doses were significantly reduced below the clinically significant level of 8 Gy, achieving mean doses of 6.66 ± 0.52 Gy (55.5% ± 4.3%). Target coverage was achieved with D90% of 77.5% ± 12.5% and homogeneity indexes of 0.92 ± 0.1. Planning time took 5-6 hours per patient: 1.5 hours for contouring and field placement and 3.5-4.5 hours for plan optimization and dose calculations. Using a dose rate of 800 MU/min field delivery time took an average of 20.8 ± 7 minutes with average portal dosimetry quality assurance passing rates of 99.6% and 99.9% for 2%/2mm and 3%/3mm gamma analysis metrics.ConclusionVMAT lung sparing TBI via Halcyon linacs is feasible and dosimetrically acceptable, with greatest applicability to smaller patients (<100 cm). Planning and setup complexity increases dramatically for larger patients (>100 cm) due to the smaller maximum field sizes (28 x 28 cm2) achievable. Future developments in software-based automations for target delineation, multiple field matching, and plan optimization could allow for more practicable treatment of larger patients.</p>","PeriodicalId":22203,"journal":{"name":"Technology in Cancer Research & Treatment","volume":"25 ","pages":"15330338261443068"},"PeriodicalIF":2.7,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13080152/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147676578","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Genomic Justice as Reproductive Justice: Universal Coverage for Preimplantation Genetic Testing for Hereditary Breast and Ovarian Cancer Syndrome.","authors":"Versha Pleasant, Breonna Slocum, Ava Purkiss","doi":"10.1177/15330338261427326","DOIUrl":"10.1177/15330338261427326","url":null,"abstract":"<p><p>With increasing limitations on reproductive choice in the past several years, reproductive rights-often relegated to abortion access and contraception-have become a critical consideration for American clinicians and patients. We implore the medical community to expand its understanding of reproductive autonomy by illuminating an overlooked community: those with hereditary breast and ovarian cancer syndrome. For those with pathogenic/likely pathogenic variants in cancer susceptibility genes that carry a 50% inheritance pattern, such as <i>BRCA</i>, preimplantation genetic testing for monogenic disorders offers a life-altering technology that provides the option to halt the generational legacy of cancer. This service, however, is cost-prohibitive. These financial barriers create disparities that not only directly impact the immediate offspring but also have the potential to form entire generational shifts in future gene pools based on socioeconomic status. This form of healthcare injustice is unacceptable, for which the medical community can and should advocate for urgent solutions. We posit that genomic justice, specifically within the framework of reproductive justice, demands that all communities have the ability to choose whether and how they will use genomic technologies to align with their reproductive goals and values.</p>","PeriodicalId":22203,"journal":{"name":"Technology in Cancer Research & Treatment","volume":"25 ","pages":"15330338261427326"},"PeriodicalIF":2.7,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12953952/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147310187","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Tecartus Real-World Adverse Event Reporting System in a Middle-Aged and Elderly Population: A FAERS-Based Pharmacovigilance Study.","authors":"Haipeng Li, Jiaqi Yan, Yanjun Zhang, Yanqiu Li, Xinyu Liu, Luyuan Chang, Chunyu Ma, Zhenghong Li, Jingting Min","doi":"10.1177/15330338261450103","DOIUrl":"10.1177/15330338261450103","url":null,"abstract":"<p><p>BackgroundTecartus (brexucabtagene autoleucel) is an autologous CAR-T product targeting CD19, but there are many undetected and unreported adverse events (AEs).MethodsWe counted data from the US Food and Drug Administration Adverse Event Reporting System (FAERS) from Q4 2020 through Q4 2024 for proportionate analyses to assess the association between Tecartus and adverse events and important medical events (IMEs).ResultA total of 792 datasets related to Tecartus were collected. The following SOCs are significant signals: Nervous system disorders, Infections and infestations, Neoplasms benign, malignant and unspecified (incl cysts and polyps). The most common AEs are cytokine release syndrome, immune effector cell-associated neurotoxicity syndrome and neurotoxicity. With Tecartus, most AEs occur within one month, but AEs can still occur after one year of use.ConclusionBy analysing data from the real-world FAERS database, we identified additional disproportionately reported AEs, providing clinicians with more information about disproportionately reported AEs before and during treatment.</p>","PeriodicalId":22203,"journal":{"name":"Technology in Cancer Research & Treatment","volume":"25 ","pages":"15330338261450103"},"PeriodicalIF":2.7,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13167272/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147842726","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prediction Models and Prognostic Analysis of Immune-Related Acute Kidney Injury in Lung Cancer Patients.","authors":"Suying Qian, Ningjie Xu, Yihui Qu, Rongrong Zhu, Minqiao Zhang, Kanan Chen, Jing Wang, Xiaoyan Lu, Kedan Cai","doi":"10.1177/15330338261428665","DOIUrl":"10.1177/15330338261428665","url":null,"abstract":"<p><p>IntroductionImmune checkpoint inhibitors (ICIs) are extensively utilized in lung cancer patients, with documented instances of ICIs-associated acute kidney injury (ICIs-AKI). This study aims to explore a model for early recognition of ICIs-AKI.MethodsThe study involved 413 adult lung cancer patients treated with ICIs at Ningbo No.2 Hospital between Sept. 1, 2021, and June 30, 2023. Patients were followed until death or Dec. 31, 2023, and categorized into ICIs-AKI or non-AKI groups. We employed univariate and multivariate logistic regression to identify risk factors, developed both logistic regression and Multilayer Perceptron (MLP) prediction models, and used Kaplan-Meier survival analysis to assess prognosis.ResultsThe study included 381 lung cancer patients receiving ICIs treatment after excluding 32 patients. ICIs-AKI occurred in 13.39% of cases, with a median onset time of [123 (63, 303)] days. Multivariable logistic analysis identified diabetes, proteinuria, extrarenal irAEs, diuretic use, and chemotherapy as significant risk factors (all <i>P</i> < 0.05), while higher baseline eGFR levels were protective (<i>P</i> < 0.05). Two prediction models were developed: logistic regression (AUC=0.877, sensitivity=0.922, specificity=0.726) and MLP (AUC=0.950, accuracy=0.843, precision=0.847). Survival analysis showed no difference in overall survival between ICIs-AKI and non-AKI groups (HR = 1.021, 95% CI = 0.629-1.659, <i>P</i> = 0.932; adjusted HR = 0.950, 95% CI = 0.558-1.616, <i>P</i> = 0.849). AKI to CKD progression incidence was 58.82%, with no significant difference in overall survival between CKD and non-CKD groups (<i>P</i> = 0.157).ConclusionThis study offers detailed insights into ICIs-AKI, including its rate, onset timing, risk factors, and clinical features. Approximately half of the affected patients experienced spontaneous renal function recovery. Both logistic regression and MLP models effectively predicted ICIs-AKI. Importantly, neither ICIs-AKI incidence nor renal function restoration correlated with patient mortality. These findings underscore the importance of early detection and management strategies.</p>","PeriodicalId":22203,"journal":{"name":"Technology in Cancer Research & Treatment","volume":"25 ","pages":"15330338261428665"},"PeriodicalIF":2.7,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13013984/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147505010","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Artificial Intelligence for Breast Cancer Molecular Subtype Prediction From Medical Imaging: A Systematic Review of Literature.","authors":"Juan Camilo Morales-Duran, Kevin Osorno-Castillo, Gloria M Díaz","doi":"10.1177/15330338261465062","DOIUrl":"10.1177/15330338261465062","url":null,"abstract":"<p><p>BackgroundBreast cancer molecular subtypes (Luminal A, luminal B, HER2-positive, and triple-negative) are typically determined through biopsy and immunohistochemistry, procedures that are invasive and prone to interpretative variability. Artificial intelligence applied to medical imaging has emerged as a non-invasive alternative to support subtype prediction. However, methodological rigor, risk of bias and clinical translatability of existing studies remain insufficiently characterized.MethodsWe conducted a systematic review in accordance with the PRISMA 2020 guidelines. Searches were performed in Scopus, Web of Science, ScienceDirect, and PubMed to identify English-language, peer-reviewed original articles published between January 1, 2020, and March 25, 2025. Two reviewers independently screened titles and abstracts using Rayyan, retrieved potentially eligible full-text articles, and assessed risk of bias and applicability using an AI-adapted QUADAS framework based on QUADAS-2.ResultsFrom 626 identified records, 76 full-text articles were assessed for eligibility. The AI-adapted QUADAS framework showed that 67 of these 76 articles were excluded because they presented a high or unclear risk of bias in at least one evaluated domain. Consequently, only 9 studies were judged to have a low risk of bias and were included in the qualitative synthesis. The included evidence was dominated by studies using dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI), with additional contributions from ultrasound-based approaches. The methodological strategies ranged from radiomics-based machine learning models to deep learning architectures.DiscussionIntegrating radiomic signatures with clinical predictors may improve performance in selected clinical scenarios, and peri-tumoral information alongside delayed DCE-MRI phases can contribute complementary diagnostic value. Nevertheless, the small number of low-risk studies highlights the need for standardized acquisition and preprocessing reporting, patient-level data splitting, robust external validation, and broader data availability to strengthen the clinical translation and generalizability of AI-based molecular subtyping.</p>","PeriodicalId":22203,"journal":{"name":"Technology in Cancer Research & Treatment","volume":"25 ","pages":"15330338261465062"},"PeriodicalIF":2.7,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13401657/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148593223","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Gut Microbiota-Ovarian Cancer Axis: Mechanisms of Influence and Therapeutic Implications.","authors":"Jiajie Mao, Huijing Bao","doi":"10.1177/15330338261428216","DOIUrl":"10.1177/15330338261428216","url":null,"abstract":"<p><p>Ovarian cancer (OC), one of the most lethal gynecological malignancies, urgently requires breakthrough diagnostic and therapeutic strategies due to its low survival rate and high recurrence rate. The gut microbiota (GM), which colonizes the human gastrointestinal tract, significantly influences human health. Recent technological advancements have enabled deeper investigation into tumor-bacteria interactions. The GM profoundly participates in OC initiation, progression, and treatment resistance by dynamically regulating the host's immune response, metabolism, and inflammatory microenvironment. This review focuses on three primary mechanisms by which the GM influences OC development and its impact on cancer therapies (chemotherapy, immunotherapy, and targeted therapy). At the mechanistic level, GM dysbiosis promotes OC through multiple pathways: (1) Modulating the tumor microenvironment (TME), including inducing immunosuppressive cell infiltration and impairing anti-tumor immunity; (2) Interfering with estrogen metabolism, thereby elevating bioactive estrogen levels; (3) Producing metabolites that mediate systemic inflammatory signaling and energy metabolism reprogramming. These alterations collectively drive tumor proliferation and metastasis. Although microbiota-based interventions offer novel opportunities for precision therapy in OC, clinical translation faces challenges such as mechanistic complexity and individual heterogeneity. Future research should integrate multi-omics technologies and large-scale clinical trials to advance microbiota modulation strategies from bench to bedside, thereby improving OC prognosis.</p>","PeriodicalId":22203,"journal":{"name":"Technology in Cancer Research & Treatment","volume":"25 ","pages":"15330338261428216"},"PeriodicalIF":2.7,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12954004/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147345293","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Role of High-Intensity Focused Ultrasound as a Local Consolidative Therapy in Multimodal Conversion Treatment for Colorectal Liver Metastases: A Case Series.","authors":"Guangtan Du, Jiashuo Li, Junwei Wang, Lihua Zhang, Yanfang Xu, Ning Yu, Linqian Li, Haowen Liu, Qianqian Liu, Jialin Song, Wensheng Qiu, Shasha Wang","doi":"10.1177/15330338261461451","DOIUrl":"10.1177/15330338261461451","url":null,"abstract":"<p><p>IntroductionThis retrospective case series evaluated the feasibility, safety, and potential clinical role of high-intensity focused ultrasound (HIFU) as local consolidative therapy (LCT) in patients with initially unresectable colorectal liver metastases (CRLM).MethodsWe retrospectively reviewed five patients with CRLM between 2019-2023 who underwent HIFU ablation in addition to systemic chemotherapy. Tumor response was assessed by contrast-enhanced MRI using modified Response Evaluation Criteria in Solid Tumors (mRECIST). Adverse events, conversion to resectability, and survival outcomes were analyzed.ResultsAll five patients underwent R0 resection after treatment incorporating systemic chemotherapy, HIFU, and surgery (median HIFU-to-surgery interval 383 days; range 17-1361 days), suggesting potential utility of HIFU both as immediate consolidation and as a long-term bridge-to-resection therapy. Only mild, self-limiting adverse events (transient liver enzyme (AST/ALT) elevation and local edema) were observed; no severe complications occurred. Median overall survival (OS) from diagnosis of liver metastases was 63.8 months, with 1-, 2-, 3-, and 5-year OS rates of 100%, 100%, 80%, and 60%, respectively. Median OS from the date of first HIFU treatment was 51.4 months (1-, 2-, 3-, and 5-year rates: 100%, 100%, 80%, and 60%).ConclusionsHIFU appears to be a safe local ablative technique and may be integrated into multimodal management of initially unresectable CRLM, and may support conversion to curative-intent resection with encouraging survival outcomes in this small series. Larger prospective studies are warranted to validate these findings and define optimal patient selection and treatment sequencing.</p>","PeriodicalId":22203,"journal":{"name":"Technology in Cancer Research & Treatment","volume":"25 ","pages":"15330338261461451"},"PeriodicalIF":2.7,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13260982/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148219883","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effect of Perioperative Glutamine-Enhanced Parenteral Nutrition on Short-Term Outcomes in Colorectal Cancer Patients Undergoing Radical Resection: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.","authors":"Yong Huang, Xiuzhi Yang, Songhan Qin, Tao Zhang, Ming Xie, Jiwei Wang","doi":"10.1177/15330338261438204","DOIUrl":"10.1177/15330338261438204","url":null,"abstract":"<p><p>BackgroundParenteral glutamine (Gln) supplementation can enhance the immune function of patients with colorectal cancer(CRC), regulate inflammatory response, nitrogen balance and protein synthesis, reduce the morbidity of postoperative complications and shorten the length of hospitalization. However, some guidelines and clinical studies have questioned the rationality of using glutamine-containing immunonutrition support in the perioperative period of CRC. Therefore, we conducted a meta-analysis of the effects of perioperative glutamine-enriched parenteral nutrition on short-term postoperative clinical outcomes in patients with CRC.MethodsA comprehensive search of all relevant literature from the default date to June 2025 was performed using the following databases: PubMed, Embase, Web of Science, Cochrane Library, China Biology Medicine Database (CBM), China National Knowledge Infrastructure (CNKI), VIP Medical Information System (VIP), and Wanfang electronic database. RevMan 5.3 software was used for the meta-analysis. We calculated the outcomes using random- and fixed-effects models.ResultsSeventeen single-center randomized controlled trials (RCTs) involving 950 patients with CRC were included. The control group consisted of 470 patients who received traditional parenteral nutrition therapy and the experimental group consisted of 480 patients who received parenteral nutrition with Gln. The analyses showed that perioperative Gln-enhanced parenteral nutrition reduced the morbidity of infectious complications (Relative Risk [RR]=0.36,95% Confidence Interval [CI]:0.23-0.58) and non-infectious complications (RR=0.27, 95% CI: 0.13-0.55). The length of hospitalization was reduced by 2.18 days (mean difference [MD] = -2.18, 95% CI: -2.59--1.78).ConclusionParenteral Gln supplementation may potentially reduced the morbidity of postoperative complications, shortened postoperative hospitalization, improved some aspects of nutritional status, immune and inflammation function in patients with CRC, based on current evidence of low-to-moderate certainty.</p>","PeriodicalId":22203,"journal":{"name":"Technology in Cancer Research & Treatment","volume":"25 ","pages":"15330338261438204"},"PeriodicalIF":2.7,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13033077/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147532837","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Gut Microbiome Alterations in Cancer and Non-cancer Adults: A Cross-Sectional Metagenomic Study.","authors":"Sabine Hazan, Guanhui Bao, Amelia Goudzwaard, Thomas Ichim, Leisha Martin, Adriana C Vidal","doi":"10.1177/15330338261470516","DOIUrl":"10.1177/15330338261470516","url":null,"abstract":"<p><p>IntroductionPrevious studies found associations between cancer and the gut microbiome. Thus, we aimed to investigate the gut microbiome composition in adults with and without cancer to try to identify specific microbes that may be associated with cancer in a cross-sectional, observational, and retrospective study.MethodsStool samples from sixty participants, n=20 controls, n=25 with aggressive cancer, and n=15 with non-aggressive cancer were analyzed using Metagenomic Next Generation Sequencing. Mann-Whitney U test tests were used to examine differences in the relative abundances of bacterial genera.ResultsCompared to controls, aggressive cancer patients had statistically significantly lower levels of gut <i>Bifidobacterium, Faecalibacterium, and Collinsella,</i> (all p≤0.05), while they had higher levels of gut <i>Bacteroides</i> (p=0.015). Non-aggressive cancer patients had lower levels of gut <i>Bifidobacterium</i> compared to controls, an association that was approaching statistical significance (p=0.054).ConclusionAggressive-cancer patients showed significantly altered levels of key gut microbes compared to controls. These are preliminary associations, and thus further larger studies are needed to confirm these findings.</p>","PeriodicalId":22203,"journal":{"name":"Technology in Cancer Research & Treatment","volume":"25 ","pages":"15330338261470516"},"PeriodicalIF":2.7,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13379655/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148472936","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}